Search research articles
Contact Us
Filters
Showing results (41-50 of 53) with videos related to
Page
of 6
Sort By:
Molecular and Clinical Oncology
|
April 18, 2017
Phase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancer
Kenji Tezuka, Tsutomu Takashima, Shinichiro Kashiwagi, et al.
Cancer Chemotherapy and Pharmacology
|
February 27, 2019
A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial
Kazuhiro Nishikawa, Kenta Murotani, Kazumasa Fujitani, et al.
Springerplus
|
March 31, 2016
A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
Tsutomu Takashima, Shinya Tokunaga, Seika Tei, et al.
Cancer
|
March 25, 2025
A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G)
Nozomu Machida, Takehiro Okumura, Narikazu Boku, et al.
Anticancer Research
|
April 7, 2019
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial
Shinya Tokunaga, Tsutomu Takashima, Shinichiro Kashiwagi, et al.
Cancer Medicine
|
March 14, 2020
A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide
Koji Matsumoto, Masato Takahashi, Kazuhiko Sato, et al.
Anticancer Research
|
October 1, 2021
An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer
Tsutomu Takashima, Shigehiko Nishimura, Hidemi Kawajiri, et al.
Journal of Cancer Research and Clinical Oncology
|
August 10, 2014
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study
Hirofumi Yasui, Kei Muro, Yasuhiro Shimada, et al.
Anticancer Research
|
December 27, 2017
Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer
Tsutomu Takashima, Hidemi Kawajiri, Takeo Nishimori, et al.
The Lancet. Oncology
|
August 17, 2010
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Kei Muro, Narikazu Boku, Yasuhiro Shimada, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 53) with videos related to
Sort By:
Page
of 6
Molecular and Clinical Oncology
|
April 18, 2017
Phase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancer
Kenji Tezuka, Tsutomu Takashima, Shinichiro Kashiwagi, et al.
Cancer Chemotherapy and Pharmacology
|
February 27, 2019
A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial
Kazuhiro Nishikawa, Kenta Murotani, Kazumasa Fujitani, et al.
Springerplus
|
March 31, 2016
A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
Tsutomu Takashima, Shinya Tokunaga, Seika Tei, et al.
Cancer
|
March 25, 2025
A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G)
Nozomu Machida, Takehiro Okumura, Narikazu Boku, et al.
Anticancer Research
|
April 7, 2019
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial
Shinya Tokunaga, Tsutomu Takashima, Shinichiro Kashiwagi, et al.
Cancer Medicine
|
March 14, 2020
A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide
Koji Matsumoto, Masato Takahashi, Kazuhiko Sato, et al.
Anticancer Research
|
October 1, 2021
An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer
Tsutomu Takashima, Shigehiko Nishimura, Hidemi Kawajiri, et al.
Journal of Cancer Research and Clinical Oncology
|
August 10, 2014
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study
Hirofumi Yasui, Kei Muro, Yasuhiro Shimada, et al.
Anticancer Research
|
December 27, 2017
Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer
Tsutomu Takashima, Hidemi Kawajiri, Takeo Nishimori, et al.
The Lancet. Oncology
|
August 17, 2010
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Kei Muro, Narikazu Boku, Yasuhiro Shimada, et al.
Page
of 6